Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

Creative Devices, Inc.444 Whiton Rd. Neshanic Station, NJ 08853

UEI: SLED_0544334776B8123B

Creative Devices, Inc.444 Whiton Rd. Neshanic Station, NJ 08853 is a federal contractor, registered under UEI SLED_0544334776B8123B. It has been awarded $125,000 across 1 federal contract. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Gsa/fas Region 7 Acqusition Center.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_0544334776B8123B

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Gsa/fas Region 7 Acqusition Center$125.0K100%

Awards by NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)$125.0K100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in Creative Devices, Inc.444 Whiton Rd. Neshanic Station, NJ 08853's top NAICS codes and agencies

Evaluation of a Lead NNMT Inhibitor in Humanized M

Solicitation # 75N98026Q00941

The National Institutes of Health, Office of the Director, intends to award a non-competitive, firm-fixed price contract to GemPharmatech LLC for the evaluation of a lead NNMT inhibitor using a humanized nicotinamide N-methyltransferase mouse model, a model uniquely developed and maintained by GemPharmatech under prior NIH funding. This acquisition is conducted under streamlined commercial item procedures and is not expected to exceed the simplified acquisition threshold, with authority derived from FAR 12.603 and 41 U.S.C. 1901, and justified under the sole source exception for unique capabilities, as GemPharmatech is the only entity with the cryopreserved sperm and breeding resources necessary to regenerate the required mouse colony essential for generating scientifically relevant efficacy data due to the inhibitor's species-specific activity. The solicitation number is 75N98026Q00941, issued as a combined synopsis and solicitation without competitive procedures, and responses are due by August 19, 2026. The work falls under NAICS code 541714 for Research and Development in Biotechnology with a small business size standard of 1,000 employees, and this requirement is not set aside for small business. The contract will be managed by the NIH Office of Acquisitions based in Bethesda, Maryland, with the primary point of contact being Johnstona C. Johnston, reachable via email. All provisions and clauses follow those in effect through the Federal Acquisition Circular dated August 4, 2026, and the notice serves as the complete and only solicitation document; no additional written solicitation will be issued. The performance location is not specified beyond the federal agency's administrative details.

National Institutes Of Health Olao

POSTED

DEADLINE

Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak

Solicitation # 75F40126Q00327

The contract seeks sequencing services for the Bundibugyo virus disease (BDBV) during the 2026 outbreak, with solicitation number 75F40126Q00327 issued by the FDA Office of Acquisition and Grant Services under the U.S. Department of Health and Human Services. The opportunity was posted on August 4, 2026, with responses due by August 10, 2026, at 4:00 PM Eastern Time, and no set-aside is applicable, meaning it is open to all eligible vendors. The North American Industry Classification System code is 541714, indicating it falls under research and development in the biological sciences. Performance location details are not specified, but the contracting office is based in Rockville, Maryland, 20852, and the primary point of contact is Ryan Alexander, reachable via email at ryan.alexander@fda.hhs.gov. The solicitation is accessible through the SAM.gov platform for further details and submission.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Yeast Two-Hybrid (Y2H) Screening Service

Solicitation # 1232SA26Q1181

The U.S. Department of Agriculture’s Agricultural Research Service is soliciting quotations for Yeast Two-Hybrid (Y2H) Screening Services under solicitation number 1232SA26Q1181, issued as a combined synopsis and solicitation in accordance with FAR Part 12 for commercial items. This acquisition is exclusively reserved for small business concerns, with the North American Industry Classification System code 541714 for Research and Development in Biotechnology and a size standard of 1,000 employees, making it a total small business set-aside. Only responsible small business sources may submit quotations, which will be evaluated without the issuance of a separate written solicitation. The quote submission deadline is August 28, 2026, at 22:00 Eastern Time, with the solicitation publicly posted on August 4, 2026, and responses due to the USDA ARS office located in Beltsville, Maryland. The performance of the Y2H screening services is required to take place in Ithaca, New York, 14853. The primary point of contact for inquiries is Kerrie Hodges, reachable via email at kerrie.hodges@usda.gov. The contract is being procured by the USDA ARS Affiliated Programs and Development office and is intended to support research activities for the Robert W. Holley Center for Agriculture and Health. Interested parties must submit their quotations through the SAM.gov platform using the provided UI link, and all responses must comply with the commercial item procurement procedures outlined in FAR Part 12. No further documentation or separate solicitation documents will be issued.

USDA Ars Afm Apd

POSTED

DEADLINE

Solicitation # 1232SA26Q0963

This solicitation, numbered 1232SA26Q0963, is a combined synopsis and request for quotation for genotyping services under FAR Part 12, with no separate written solicitation to follow. It is a total small business set-aside, restricted exclusively to small businesses as defined by the NAICS code 541714 and the 1,000-employee size standard. All responsible small business sources are encouraged to submit quotations, which will be evaluated based on criteria outlined in Attachment 1, which includes the full terms, conditions, and evaluation parameters. The solicitation incorporates provisions and clauses by reference, accessible electronically at www.acquisition.gov. The contract is issued by the USDA ARS AFM APD, with the office located in Beltsville, Maryland, and performance required in Maricopa, Arizona, ZIP 85138. Responses are due by August 12, 2026, at 7:00 p.m. Eastern Time, and the opportunity was posted on August 4, 2026. The primary point of contact for inquiries is Frank Palmer, reachable via email at frank.palmer@usda.gov, and additional details can be viewed on the SAM.gov website at the provided UI link.

USDA Ars Afm Apd

POSTED

DEADLINE

AN11--36C25226R0084 - TBI research with Arraystar Inc FY2026

Solicitation # 36C25226R0084

The Department of Veterans Affairs is seeking information from potential vendors to support a sole source procurement for Methylated and hydroxymethylated DNA immunoprecipitation sequencing (MeDIP-seq and hMeDIP-seq) services under solicitation number 36C25226R0084. This effort is part of a TBI research project at the William S Middleton VA Medical Center in Madison, Wisconsin, aimed at understanding epigenetic changes—specifically the roles of 5-methylcytosine and 5-hydroxymethylcytosine—in secondary brain damage following trauma. The contract requires comprehensive sequencing and data analysis of mouse brain tissue samples from adult and aged males and females to identify sex- and age-specific patterns. The work must be performed using the same tissue samples for both MeDIP and hMeDIP to minimize variability and ensure reliable comparative results. The vendor will deliver raw sequencing data in Fastq format, quality control reports, analytical summaries, and final project reports in Excel, PDF, and PNG formats within 56 to 70 days of contract start. Submission of capability statements is required by August 10, 2026, via email only, with no phone inquiries accepted, and must include customer references and technical proof of capability. This is not a solicitation or request for proposals but a sources sought notice to justify a sole source award under 41 U.S.C. 1901, as the VA believes only one vendor can meet the highly specialized scientific requirements. The principal investigator will evaluate all submissions due to the technical nature of the research and will determine vendor suitability. The contract, if awarded, will be a firm fixed price agreement for one year, with no option periods, running from August 10, 2026, to August 9, 2027. All deliverables must be transmitted via USB drive, as the research laboratory operates in an affiliate space disconnected from the VA network. Responses must be emailed to Tiarrah Turner at the VA Great Lakes Acquisition Center in Milwaukee, Wisconsin, with attachments not exceeding 8 MB each. The government retains full discretion to proceed with sole source negotiation regardless of responses received. No federal funds are allocated under the Recovery Act for this procurement.

252-NETWORK Contract Office 12 (36C252)

POSTED

DEADLINE

Emerging Infections Network - Research for Preventing, Detecting, and Managing Travel-associated Infectious Diseases

Solicitation # RFA-CK-26-035

This funding opportunity aims to strengthen the detection, prevention, and management of infectious diseases among international travelers by establishing a robust research network focused on real-world surveillance and clinical insights. The initiative seeks to improve the speed and accuracy of outbreak detection, enhance understanding of disease progression, refine diagnostic and treatment approaches, and optimize genomic surveillance—all with the goal of advancing U.S. global health security. Research must directly address public health challenges linked to travel-associated infections, with an emphasis on generating actionable data that informs guidelines and improves patient care outcomes. The program includes two distinct but complementary components: a clinic-based sentinel network that collects clinical and epidemiological data from healthcare settings serving travelers, and a sentinel detection system embedded within international transportation hubs such as airports and seaports to capture early signals of emerging threats. Applicants may submit proposals for one or both components, but if a single applicant receives top scores for both, funding will be awarded only for Component B, ensuring resources are directed toward the most critical point of pathogen introduction. Applications must be submitted by November 5, 2026, through the CDC’s solicitation RFA-CK-26-035, with direct inquiries to the designated point of contact at the Centers for Disease Control and Prevention.

Centers For Disease Control And Prevention

POSTED

DEADLINE

Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_PreSolNotice_NPIVS-2027

The U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is seeking qualified contractors to support the ongoing Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. Contractors must be capable of furnishing all necessary services, personnel, equipment, materials, and U.S.-based facilities to produce vaccines, antigens, and adjuvants for pandemic influenza and other viruses with pandemic potential. To be eligible, offerors must either hold an active U.S. influenza vaccine license from the FDA or have submitted a Biologics License Application for a seasonal or pandemic influenza vaccine. The program demands the generation and submission of comprehensive regulatory data—including analytical, nonclinical, clinical, and chemistry, manufacturing, and controls (CMC) information—to the FDA to enable rapid decision-making and maintain manufacturing readiness during interpandemic periods. The anticipated contract is an indefinite delivery, indefinite quantity (IDIQ) vehicle with a base performance period of 60 months and the potential to extend up to 120 months if all option periods are exercised, combining both cost-reimbursement and firm-fixed-price task orders. Performance is expected to occur primarily within the United States, with the place of performance designated as Washington, D.C., and the contracting office located at 400 7th Street SW. Proposals must be submitted electronically via SAM.gov by the deadline of August 15, 2026, and are subject to evaluation based on mandatory qualification requirements, with full evaluation factors and source selection criteria expected to be detailed in the forthcoming Request for Proposals. The solicitation number is 75A50126R00001, and the NAICS code is 541714 for research and development in biotechnology. The primary point of contact for inquiries is Laura Saddison, BARDA Contracting Officer, reachable at Laura.Saddison@hhs.gov. No set-aside is planned, and full and open competition is anticipated. While packaging, marking, inspection procedures, and specific invoicing methods are not defined in this presolicitation, contractors should prepare to comply with FDA regulatory standards and anticipate the use of federal systems such as WAWF for payment processing. No contracting officer’s representative or technical representative has been designated yet, and all certifications and representations will be required upon formal proposal submission.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Convergence Special Notice

Solicitation # DARPA-SN-26-108

The Convergence program seeks to revolutionize environmental monitoring for defense operations by integrating synthetic biology and engineering to create advanced microbial biosensors capable of detecting chemical and pharmaceutical hazards in austere environments. Leveraging non-pathogenic microbial consortia built on well-characterized, safe host organisms like E. coli, the initiative focuses on developing modular biological systems that translate environmental inputs into standardized, detectable outputs. The program’s development follows a structured four-tiered approach, progressing from component-level design and integrated payload engineering to full system integration within a microbial chassis, ultimately aiming for a deployable platform ready for U.S. and international regulatory certification. This systematic progression ensures that each layer of functionality is rigorously validated before scaling to operational readiness. To enable safe, responsible, and globally viable deployment, the program includes a dedicated ecosystem of testing and collaboration. Performance and safety validation will first occur within the United States before exploring international adoption, with two specialized working groups guiding the process: one focused on navigating socio-political landscapes and local environmental regulations, and another managing cooperative use cases and deployment protocols with global allies. Administered by DARPA, the solicitation under number DARPA-SN-26-108 invites multidisciplinary teams in synthetic biology, environmental science, and engineering to contribute to this initiative, with responses due by August 6, 2026. The program is headquartered in Arlington, Virginia, and is led by Mark Salvador, with the goal of delivering a scalable, secure, and globally interoperable biosensor platform for the protection of military personnel.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Multiscale Reasoning For Human Physiology RFI

Solicitation # DARPA-SN-26-100

The Defense Advanced Research Projects Agency’s Biological Technologies Office is seeking input on cutting-edge technologies that enable multiscale reasoning across human physiology through this Request for Information, identified as DARPA-SN-26-100. The focus is on emerging tools including artificial intelligence systems, foundation models, computational frameworks, and datasets capable of integrating biological, physiological, and clinical data across multiple scales—from molecular and cellular levels to organ systems and whole-body responses. The goal is to advance the ability to model, predict, and interpret complex human physiological behavior using AI and data-driven approaches, with interest in non-traditional performers and innovative solutions from industry, academia, government labs, and healthcare organizations. Responses are due by August 10, 2026, and the solicitation falls under NAICS code 541714 for research and development in the physical, engineering, and life sciences. All submissions should be directed to Dr. Roozbeh Jafari, Program Manager at DARPA/BTO, via bioreasoning@darpa.mil. The office is located in Arlington, Virginia, and while no specific place of performance is defined, selected technologies may be developed and evaluated through future DARPA programs. This RFI does not constitute a solicitation for proposals or obligations but aims to inform upcoming funding opportunities in the field of physiological modeling and AI-driven biological insight.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Trusted Partner Program Coming Soon

Solicitation # W911NF26RA009

The U.S. Army, through the Army Research Office and the Office of Contracting at Research Triangle Park, North Carolina, is issuing a presolicitation for the Trusted Partner Program, a multiple-award IDIQ contract aimed at establishing a cadre of trusted academic partners—including institutions of higher education and their affiliated entities—to conduct rapid, sensitive basic and applied scientific research in support of national defense priorities. The solicitation, numbered W911NF26RA009, targets research in Scaled Directed Energy and Scaled Hypersonics, requiring multidisciplinary expertise across physics, electronics, chemistry, materials science, information sciences, and biology, with an emphasis on integrating these fields to address complex Army needs. The base performance period is five years, beginning September 2026, with an optional five-year extension, bringing the total potential contract value to $400 million, with individual task orders to be issued under cost-plus-fixed-fee or firm-fixed-price arrangements. Offerors must submit proposals in five separate volumes, each as a searchable PDF, along with a supplemental unclassified video pitch between three and seven minutes in length, formatted in MPEG-4 at 1080p resolution. Proposals are due by 4:00 PM Eastern Time on July 15, 2026, and must be emailed to the designated point of contact. Evaluation will be conducted based on five factors, ranked in order of importance: Technical (most important), Management, Past Performance, Small Business, and Cost & Business Structure (least important non-cost factor). No numerical weights are assigned, and the award will be made using a trade-off process emphasizing superior technical merit over price, with the expectation that all non-cost factors combined carry significantly greater weight than cost. The Technical factor includes equally weighted subfactors centered on expertise in six core disciplines and six critical interdisciplinary projects, assessed using adjectival ratings from BLUE (outstanding, low risk) to RED (unacceptable, unawardable). Compliance with regulatory requirements is strict: contractors must maintain active UEI and CAGE codes in SAM, adhere to cybersecurity maturity model certification requirements, and submit all deliverables in accordance with Department of Transportation packaging standards and marking requirements that include contract number, project title, and sensitive data classification. Travel is highly regulated, requiring prior COR approval and adherence to JTR per diem limits; OCONUS travel necessitates SPOT registration and a Letter of Authorization. Organizational conflicts of interest will be rigorously assessed, and all

W6QK Acc-Apg Durham

POSTED

DEADLINE

Multimodal Sensor Integration and Signal Fusion EngineeringThe contract seeks integration of multiple sensing modalities into a unified platform designed for real-time pharmaceutical inspection, emphasizing synchronized signal correlation and advanced noise reduction techniques. The project requires the engineering of a robust system capable of fusing data from diverse sensor types to enhance detection accuracy, reliability, and speed in identifying product defects or anomalies during manufacturing processes. Development must ensure temporal and spatial alignment of signals, adaptive filtering for environmental and operational interference, and seamless interoperability across hardware and software components to support continuous, high-fidelity monitoring. This subcontract, under NAICS code 541714 and sponsored by the Advanced Research Projects Agency for Health within the Department of Health and Human Services, targets innovation in sensor fusion technologies with a specific focus on quality assurance in pharmaceutical production. The place of performance is designated as Washington DC with a zip code of 20005, and proposals must be submitted by August 20, 2026. The initiative aims to advance detection capabilities beyond conventional single-sensor approaches, enabling next-generation inspection systems that meet stringent regulatory standards through data-driven, real-time analytics.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Sources Sought – RRBS Sequencing Services

Solicitation # 36C241-26-AP-4037

The Department of Veterans Affairs is seeking qualified Service-Disabled Veteran-Owned Small Businesses and Veteran-Owned Small Businesses to provide Reduced Representation Bisulfite Sequencing services for a neurodegenerative disease research program involving approximately 269 de-identified human post-mortem choroid plexus tissue samples. The scope includes comprehensive sample handling and quality control, bisulfite conversion, library preparation, Illumina paired-end sequencing generating about 30 million read pairs per sample, and downstream bioinformatics analysis such as raw data alignment, methylation calling, and genome browser track generation, with an expected turnaround time of six to eight weeks. This notice is issued for market research purposes under the Veterans First Contracting Program and is intended to evaluate potential for a set-aside under the VA Rule of Two, ensuring opportunities for SDVOSBs and VOSBs. All interested parties must submit a capability statement detailing their technical expertise, business size and status as an SDVOSB or VOSB, and facility location by 11:00 AM EST on August 12, 2026, to Chelsea Cortright at Chelsea.Cortright@va.gov with the subject line referencing ID# 36C241-26-AP-4037. The opportunity is not a solicitation or request for proposals, and no contract will be awarded directly from this notice. The effort is managed by the 241-NETWORK Contract Office 01 based in Togus, Maine, with performance occurring in Bedford, Massachusetts, under NAICS code 541714 for analytical laboratory services. Additional inquiries can be directed to Jennifer Fiore, the secondary point of contact.

241-NETWORK Contract Office 01 (36C241)

POSTED

DEADLINE

Research service necessary to execute a NAMRU SOUTH Zika study in Panama.

Solicitation # ERP_PR_1301393620

Naval Medical Research Unit South is seeking research services to support its Virology Department’s febrile and respiratory surveillance study, specifically in support of a Zika virus study in Panama. The government has conducted market research and determined that only Fundacion Ciudad del Saber possesses the unique capability to fully meet the technical and operational requirements of the study, making the procurement eligible for a sole source award under FAR 13.106-1(b)(i). No competitive solicitation exists, and this notice serves solely as an opportunity for other potential vendors to demonstrate their capability to perform the work. Interested parties must submit a capability statement not exceeding five pages in 10-point font or larger, containing detailed management, technical, and cost information with convincing evidence of their ability to fulfill the requirement. Submissions must be sent via email as a Word or PDF attachment to genaro.m.vasquez.ln@health.mil with the subject line “ERP PR_1301393620” no later than 12:00 PM local time on August 11, 2026. Responses consisting only of questions or requests for clarification will not be accepted. The government retains full discretion to proceed with a sole source award or open a competitive process based on the submissions received. The contracting office is located in Washington, DC, and the primary point of contact is Genaro Vasquez.

Naval Medical Research Unit South

POSTED

DEADLINE

Bioinformatics and Data Analysis for Biomarker ResearchThe contract titled Bioinformatics and Data Analysis for Biomarker Research seeks to deliver computational analysis of high-throughput sequencing data with the goal of identifying and validating biomarker signatures, accompanied by the generation of detailed research reports. This effort is classified as a subcontract under NAICS code 541714 and is managed by the Department of Veterans Affairs through its 245-NETWORK Contract Office 5. The work is to be performed at a location in Washington, D.C., with a zip code of 20422. The opportunity was posted on July 24, 2026, and responses are due by August 7, 2026, at 5:00 PM EST. Although no specific set-aside designation is indicated, the contract is structured to support advanced bioinformatics capabilities essential for translational research in biomarker discovery.

245-NETWORK Contract Office 5 (36C245)

POSTED

DEADLINE

Illumina Reagent Kits

Solicitation # 1301397256

The United States Department of the Naval Medical Research Command intends to award a sole source contract to Illumina, Inc. of San Diego, California, for the purchase of Illumina Reagent Kits. This procurement is not a competitive solicitation, but responses received will be considered if submitted. The action is classified under NAICS code 541714 and will be conducted under FAR Part 12 guidelines for commercial items. All vendors must be registered in the Systems for Award Management (SAM) and possess a Unique Entity Identification Number (UEI) to be eligible for award, with SAM registration available free of charge through sam.gov or by calling (866) 606-8220. The contract is identified by solicitation number 1301397256, posted on July 23, 2026, with a response deadline of August 7, 2026. The contracting office is located in Silver Spring, Maryland, with performance expected in Frederick, Maryland. Primary point of contact is Shamai Carter, reachable at shamai.m.carter.civ@health.mil, with Nataki Johnson as the secondary contact.

Naval Medical Research Center

POSTED

DEADLINE

AI-Driven Predictive Maintenance for Oilfield EquipmentThe contract titled AI-Driven Predictive Maintenance for Oilfield Equipment seeks to develop advanced AI and machine learning models designed to forecast failures in critical oilfield equipment including pumps, compressors, and valves. The primary objective is to reduce unplanned downtime by 20 percent through proactive maintenance scheduling enabled by predictive analytics. This subcontract is posted under the NAICS code 541714, which pertains to research and development in the physical, engineering, and life sciences, indicating a focus on technical innovation in industrial applications. The contract is managed by the National Energy Technology Laboratory under the Department of Energy, with a response deadline of September 22, 2026, and a posting date of July 23, 2026. While specific performance locations and points of contact are not detailed, the scope implies deployment across oilfield operations requiring real-time equipment monitoring and data-driven decision-making. Success will be measured by achieving the targeted reduction in downtime, demonstrating the model’s reliability and operational impact in high-stakes industrial environments.

National Energy Technology Laboratory

POSTED

DEADLINE

in about 2 months

Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration AwardThe Congressionally mandated Clinical and Translational Science Awards (CTSA) Program aims to accelerate the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health by funding a national network of academic medical centers. This network provides essential infrastructure, expertise, training, and collaborative platforms needed to move research from the laboratory into clinical practice and community health settings. The current opportunity is a forecast for a limited competition soliciting applications for the Collaborative and Innovative Acceleration Award, designed to support the development and implementation of novel approaches, technologies, or models that amplify the impact of translational research and expedite the delivery of effective therapies to all populations. Funding is authorized under Sections 301 and 405 of the Public Health Service Act, and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Eligible organizations may apply under this limited competition, and proposals will undergo standard National Institutes of Health peer review, with funding awarded only to meritorious applications. The announcement is issued by the National Institutes of Health, under the Department of Health and Human Services, with specific inquiries directed to the Division of Clinical Innovation at NCATS. The forecast was posted on July 20, 2026, and further details can be accessed through the official grants.gov listing, though no set-aside type, NAICS code, or specific place of performance is indicated.

National Institutes Of Health

POSTED

DEADLINE

Hypoxia Chamber Services

Solicitation # 80JSC026Q0008

NASA Johnson Space Center is soliciting offers for Hypoxia Chamber Services under solicitation number 80JSC026Q0008 to support research on the physiological, cognitive, and clinical effects of mild hypobaric hypoxia as part of the Artemis Program. The contract requires comprehensive services including infrastructure, personnel, training, materials, food, supplies, and operational support necessary to conduct controlled hypoxia experiments. This is a combined synopsis and solicitation issued under FAR Subpart 12.6, with no written solicitation to follow, and all information is contained within the posted notice and attachments, particularly Attachment A for the Performance Work Statement and Attachment D for additional submission requirements. The NAICS code is 541714 with a size standard of 1,000 employees, and offerors must self-certify their size status. Evaluation will prioritize Technical Acceptability and Past Performance as significantly more important than Price, though Price becomes increasingly relevant when proposals are closely matched in technical merit. All submissions must include completed representations and certifications per FAR 52.212-3 and comply fully with FAR 52.212-1 and 52.212-4. Proposals must be submitted electronically via email to the designated NASA contacts no later than 1:00 PM CST on August 24, 2026, with questions due by July 29, 2026. The Government assumes no responsibility for electronic submission failures, and late submissions will be rejected per FAR provisions. The place of performance is Houston, Texas, and the Ombudsman clause is applicable for dispute resolution.

NASA Johnson Space Center

POSTED

DEADLINE